-
2023-04-17
优锐医药恩塞芬汀中国III期临床试验 全国研究者会顺利召开
2023年4月7日,由优锐医药主办的用于治疗慢性阻塞性肺疾病(COPD)新药恩塞芬汀 中国III期临床试验 ENHANCE - CHINA (RPL554 - CPC001)全国研究者会在中国广州隆重召开
-
2023-04-10
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of chronic obstr
-
2023-04-06
Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel
-
2023-03-14
Bentrio™鼻喷剂 活力上线 亮相中国香港!
优锐医药亚太区域首款商业产品,Bentrio™鼻喷剂已在中国香港首发上市!
-
2023-03-03
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Altamira Therapeutics Ltd. reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control.
-
2023-02-14
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting
Altamira Therapeutics Ltd. announced that data from three clinical studies with the Company's Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)
-
2023-01-24
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
Altamira Therapeutics Ltd. provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR)
-
2022-12-20
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD